The regulation of aquaporin-2 (AQP2) water channel excretion in the collecting duct depends mainly on the action of vasopressin (AVP). Recently, however, other regulatory factors have been identified: atrial natriuretic factor, oxytocin and prostaglandins. In healthy volunteers (5 males, 5 females; mean age 23 ± 3 years) we therefore evaluated the effect of a stable analogue of prostacyclin-2 (PGI2), iloprost, on renal function and on the urinary excretion of AQP2 (U-AQP2). After 6 h of iloprost infusion, U-AQP2 increased from 0.8 ± 0.15 to 1.8 ± 0.2 pmol/mg creatinine (p < 0.001), while the urinary flow rate increased from 1.4 ± 0.2 to 1.8 ± 4 (p < 0.01). No significant change was found in the AVP serum concentration, with a basal value of 3.17 ± 0.12 vs. 3.15 ± 0.12 pg/ml after 6 h of prostacyclin infusion. All the values returned to pre-study levels after a recovery period of 6 h. In conclusion, the PGI2 analogue, iloprost, can induce U-AQP2 excretion independent of AVP.

Keywords:
Aquaporin-2, Iloprost, Prostacyclin-2
1.
Fushimi K, Uchida S, Hara Y, Hirata Y, Marumo F, Sasaki S: Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature 1993;361:549–552.
2.
Sasaki S, Fushimi K, Saito H: Cloning characterization and chromosomal mapping of human aquaporin of collecting duct. J Clin Invest 1994;93:1250–1256.
3.
Nielsen S, Di Giovanni SR, Christensen EI, Knepper MA, Harris HW: Cellular and subcellular immunolocalization of vasopressin-regulated water channel in rat kidney. Proc Natl Acad Sci USA 1992;90:11663–11667.
4.
Marples D, Knepper MA, Nielsen S: Captopril increases aquaporin-2 water channel expression despite causing polyuria in rats. J Am Soc Nephrol 1998;9:23A.
5.
Marples D, Knepper MA, Nielsen S: Inhibition of prostaglandins abolishes thirsting-induced AQP2 expression in collecting duct. J Am Soc Nephrol 1998;9:22A.
6.
Sakairi Y, Jacobson HR, Noland TD, Breyer MD: Luminal prostaglandin E receptors regulate salt and water transport in rabbit collecting duct. Am J Physiol 1995;38:F257–F265.
7.
Orloff J, Handler JS, Bergstrom S: Effect of prostaglandin (PGE1) on the permeability response of toad bladder to vasopressin. Theophylline and adenosine 3′,5′ monophosphate. Nature 1965;205:397.
8.
Hebert RL, Regnier L, Peterson LN: Rabbit cortical collecting ducts express a novel prostaglandin receptor. Am J Physiol 1995;268:F145–F154.
9.
Menè P, Dunn MJ: Vascular, glomerular and tubular effects of angiotensin II, kinins and prostaglandins; in Seldin DW, Giebisch G (eds): The Kidney, Physiology and Pathophysiology, ed 2. New York, Raven Press, 1992, pp 1205–1248.
10.
Coleman RA, Kennedy I, Humprey PP, Bunce K, Lumley PA: Prostanoids and their receptors; in Hansch C (ed): Comprehensive Medicinal Chemistry. Oxford, Pergamon, 1989, pp 643–714.
11.
Angeli P, Gatta A, Caregaro L, Menon F, Sacerdoti D et al: Effects of iloprost, a prostacyclin analog derivative, on renal plasma flow, renal function and renin aldosterone system in humans. Clin Pharmacol Ther 1988;44:211–216.
12.
Kanno K, Sasaki S, Hirata Y: Urinary excretion of aquaporin-2 in patients with diabetes insipidus. N Engl J Med 1995;332:1540–1545.
13.
Ohara M, Martin YP, Xu D, St John J, et al: Upregulation of aquaporin-2 water channel expression in pregnant rats. J Clin Invest 1998;101:1076–1083.
14.
Patil RV, Han Z, Way MB: Regulation of water channel activity of aquaporin 1 by arginine vasopressin and atrial natriuretic peptide. Biochem Biophys Res Commun 1997;238:392–396.
15.
Schlondorff D: Renal prostaglandin synthesis: Sites of production and specific action of prostaglandins. Am J Med 1986;81(suppl 2B):1–11.
16.
Griglewsky RJ, Stork G: PGI2 and its stable analogue iloprost; in Griglewsky RJ, Stork G (eds): Prostaglandins. Berlin, Springer, 1987.
17.
Baumgarten R, Van de Pol MHJ, Deen PMT, Van Os CH, Wetzels JFM: Dissociation between urinary excretion of aquaporin 2 and vasopressin action in healthy volunteers. J Am Soc Nephrol 1998;9:15A.
18.
Grenier FC, Allen ML, Smith WL: Interrelationships among prostaglandins, vasopressin and cAMP in renal papillary collecting tubule cells in culture. Prostaglandins 1982;24:547–565.
19.
Veis JH, Dillingham MA, Beri T: Effects of prostacyclin on the cAMP system in cultured rat inner medullary collecting duct cells. Am J Physiol 1990;258:F1218–F1223.
20.
Villa E, Garcia-Robles R, Haas J, Romero JC: Comparative effect of PGE2 and PGI2 on renal function. Hypertension 1997;30:664–666.
21.
Ylitalo P, Kaukinen S, Nurmi AK, Seppala E, Pessi T, Vapaatalo H: Effects of a prostacyclin analog iloprost on kidney function, renin-angiotensin and kallikrein-kinin systems, prostanoid and catecholamines in man. Prostaglandins 1985;29:1063–1071.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.